Current status of intralesional agents in treatment of malignant melanoma.

Zawit, Misam; Swami, Umang; Awada, Hassan; Arnouk, Joyce; Milhem, Mohammed; Zakharia, Yousef

Zawit, Misam; Swami, Umang; Awada, Hassan; Arnouk, Joyce; Milhem, Mohammed; Zakharia, Yousef.

Afiliación

Zawit M; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.
Swami U; Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Awada H; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.
Arnouk J; Division of Hematology, Oncology and Blood and Marrow Transplantation and the Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.
Milhem M; Division of Hematology, Oncology and Blood and Marrow Transplantation and the Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.
Zakharia Y; Division of Hematology, Oncology and Blood and Marrow Transplantation and the Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.

Ann Transl Med ; 9(12): 1038, 2021 Jun.

Article en En | MEDLINE | ID: mdl-34277838

Palabras clave

Melanoma; intralesional; intratumoral; talimogene laherparepvec (T-VEC)

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Ann Transl Med Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: China

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google